<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ometendo</journal-id><journal-title-group><journal-title xml:lang="ru">Ожирение и метаболизм</journal-title><trans-title-group xml:lang="en"><trans-title>Obesity and metabolism</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2071-8713</issn><issn pub-type="epub">2306-5524</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/omet11887</article-id><article-id custom-type="elpub" pub-id-type="custom">ometendo-11887</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original paper</subject></subj-group></article-categories><title-group><article-title>Тиреотропный гормон, лептин и показатели инсулинорезистентности у пациентов с ожирением после бариатрических вмешательств</article-title><trans-title-group xml:lang="en"><trans-title>Thyroid-stimulating hormone, leptin and insulin resistance in patients with obesity after bariatric surgery</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5189-9365</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волкова</surname><given-names>Анна Ральфовна</given-names></name><name name-style="western" xml:lang="en"><surname>Volkova</surname><given-names>Anna R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><email xlink:type="simple">volkovaa@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8867-8654</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фишман</surname><given-names>Михаил Борисович</given-names></name><name name-style="western" xml:lang="en"><surname>Fishman</surname><given-names>Michael B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><email xlink:type="simple">michaelfishman@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0791-4705</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семикова</surname><given-names>Галина Владимировна</given-names></name><name name-style="western" xml:lang="en"><surname>Semikova</surname><given-names>Galina V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ассистент кафедры терапии </p></bio><bio xml:lang="en"><p>MD</p></bio><email xlink:type="simple">semikovagv@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pavlov First Saint Petersburg State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>21</day><month>09</month><year>2020</year></pub-date><volume>17</volume><issue>2</issue><fpage>187</fpage><lpage>192</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Волкова А.Р., Фишман М.Б., Семикова Г.В., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Волкова А.Р., Фишман М.Б., Семикова Г.В.</copyright-holder><copyright-holder xml:lang="en">Volkova A.R., Fishman M.B., Semikova G.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.omet-endojournals.ru/jour/article/view/11887">https://www.omet-endojournals.ru/jour/article/view/11887</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Функциональное состояние щитовидной железы вносит вклад в течение ожирения и ассоциированных с ним состояний. Наибольшую эффективность в лечении ожирения доказали методы бариатрической хирургии.</p></sec><sec><title>Цель</title><p>Цель. Оценить динамику массы тела, тиреоидного статуса, уровня лептина и показателей инсулинорезистентности у пациентов с ожирением после выполнения бариатрических вмешательств.</p></sec><sec><title>Методы</title><p>Методы. 74 пациента с ожирением II и III степени наблюдались после выполнения бариатрических вмешательств (рукавная гастропластика – 42 пациента, гастрошунтирование – 32 пациента); исходно оценивали индекс массы тела (ИМТ), уровень тиреотропного гормона (ТТГ), свободного Т4, уровни лептина, инсулина и глюкозы плазмы натощак; рассчитывался индекс инсулинорезистентности НОМА-IR. Динамика массы тела оценивалась по ИМТ и проценту потери избыточного ИМТ (%EBMIL). Через 3 года у 48 пациентов производили повторное измерение показателей.</p></sec><sec><title>Результаты</title><p>Результаты. Субклинический гипотиреоз (СГ) был выявлен у 36,5% пациентов с высокими степенями ожирения. Была выявлена корреляционная зависимость между ИМТ и уровнем ТТГ (R=0,5; p=0,01). НОМА-IR был повышен у большинства пациентов с ожирением II и III степени (в среднем – 4,8±1,9 нг/мл). В группе СГ уровень лептина был значимо выше, чем в группе с нормальным уровнем ТТГ 43,0±7,3 нг/мл и 33,2±4,6 нг/мл соответственно (р=0,004). Среди пациентов с исходным СГ у 45% к 3 году после БО произошло спонтанное восстановление уровня ТТГ.</p></sec><sec><title>Заключение</title><p>Заключение. В послеоперационном периоде снижение ИМТ было ассоциировано с уменьшением уровня ТТГ, лептина и HOMA-IR. Полученные данные могут отражать влияние жировой ткани на функциональное состояние щитовидной железы у пациентов с высокими степенями ожирения после бариатрических вмешательств. Это представляется крайне важным для поддержания достигнутой массы тела.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>BACKGROUND</title><p>BACKGROUND: The function of the thyroid gland effects on obesity and comorbidities. It has been proven for bariatric surgery to be the most effective in obesity treatment.</p></sec><sec><title>AIM</title><p>AIM: to evaluate the dynamics of body weight, thyroid status, leptin and insulin resistance in obese patients after bariatric surgery.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS: 74 obese patients were observed after bariatric surgery (sleeve gastrectomy – 42, gastric bypass - 32); initial body mass index (BMI), thyroid stimulating hormone, free T4, fasting plasma leptin, insulin and glucose were estimated; the insulin resistance index HOMA-IR was calculated. The dynamics of body weight was estimated by BMI and the excess BMI loss (% EBMIL). After 3 years of follow-up, 48 patients were examined.</p></sec><sec><title>RESULTS</title><p>RESULTS: Subclinical hypothyroidism (SH) was detected in 36.5% of patients with high degrees of obesity. A correlation was found between BMI and TSH level (R=0.5; p=0.01). HOMA-IR was increased in most patients with obesity of the II and III degree (4.8±1.9 ng / ml). In the SH group, the leptin level was significantly higher than in the group with a normal TSH level of 43.0±7.3 ng / ml and 33.2±4.6 ng / ml (p=0.004). Among patients with initial SH, spontaneous reduction of TSH levels occurred in 45% patients 3 years after surgery.</p></sec><sec><title>CONCLUSIONS</title><p>CONCLUSIONS: Postoperatively, the BMI decrease was associated with the decrease of TSH, leptin and HOMA-IR. The data obtained may reflect the effect of adipose tissue on the functional state of the thyroid gland in patients with high degrees of obesity after bariatric surgery. This seems to be extremely important for maintaining body weight.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ожирение</kwd><kwd>тиреотропный гормон</kwd><kwd>лептин</kwd><kwd>инсулинорезистентность</kwd><kwd>бариатрическая хирургия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>obesity</kwd><kwd>thyroid stimulating hormone</kwd><kwd>leptin</kwd><kwd>insulin resistance</kwd><kwd>bariatric surgery</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Angrisani L, Santonicola A, Iovino P, et al. Bariatric surgery worldwide 2013. Obes Surg. 2015;25(10):1822-1832. DOI:10.1007/s11695-015-1657-z</mixed-citation><mixed-citation xml:lang="en">Angrisani L, Santonicola A, Iovino P, et al. Bariatric surgery worldwide 2013. Obes Surg. 2015;25(10):1822-1832. DOI:10.1007/s11695-015-1657-z</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Захарова С.М., Савельева Л.В., Фадеева М.И. Ожирение и гипотиреоз // Ожирение и метаболизм. – 2013. – Т. 10. – № 2. – С. 54–58. [Zakharova SM, Savelieva LV, Fadeeva MI. Obesity and hypothyroidism. Obesity and metabolism. 2013;10(2):54-58. (In Russ.)] DOI:10.14341/2071-8713-4826</mixed-citation><mixed-citation xml:lang="en">Захарова С.М., Савельева Л.В., Фадеева М.И. Ожирение и гипотиреоз // Ожирение и метаболизм. – 2013. – Т. 10. – № 2. – С. 54–58. [Zakharova SM, Savelieva LV, Fadeeva MI. Obesity and hypothyroidism. Obesity and metabolism. 2013;10(2):54-58. (In Russ.)] DOI:10.14341/2071-8713-4826</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Oh JY, Sung YA, Lee HJ. Elevated thyroid stimulating hormone levels are associated with metabolic syndrome in euthyroid young women. Korean J Intern Med. 2013;28(2):180-186. DOI:10.3904/kjim.2013.28.2.180</mixed-citation><mixed-citation xml:lang="en">Oh JY, Sung YA, Lee HJ. Elevated thyroid stimulating hormone levels are associated with metabolic syndrome in euthyroid young women. Korean J Intern Med. 2013;28(2):180-186. DOI:10.3904/kjim.2013.28.2.180</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ren R, Ma Y, Deng F, et al. Association between serum TSH levels and metabolic components in euthyroid subjects: a nationwide population-based study. Diabetes Metab Syndr Obes. 2019;12:1563-1569. DOI:10.2147/DMSO.S202769</mixed-citation><mixed-citation xml:lang="en">Ren R, Ma Y, Deng F, et al. Association between serum TSH levels and metabolic components in euthyroid subjects: a nationwide population-based study. Diabetes Metab Syndr Obes. 2019;12:1563-1569. DOI:10.2147/DMSO.S202769</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Oge A, Bayraktar F, Saygili F, et al. TSH influences serum leptin levels independent of thyroid hormones in hypothyroid and hyperthyroid patients. Endocr J. 2005;52(2):213-217. DOI:10.1507/endocrj.52.213</mixed-citation><mixed-citation xml:lang="en">Oge A, Bayraktar F, Saygili F, et al. TSH influences serum leptin levels independent of thyroid hormones in hypothyroid and hyperthyroid patients. Endocr J. 2005;52(2):213-217. DOI:10.1507/endocrj.52.213</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Higa K, Ho T, Tercero F, et al. Laparoscopic Roux-en-Y gastric bypass: 10-year follow-up. Surg Obes Relat Dis. 2011;7(4):516-525. https://doi.org/10.1016/j.soard.2010.10.019.</mixed-citation><mixed-citation xml:lang="en">Higa K, Ho T, Tercero F, et al. Laparoscopic Roux-en-Y gastric bypass: 10-year follow-up. Surg Obes Relat Dis. 2011;7(4):516-525. https://doi.org/10.1016/j.soard.2010.10.019.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Brethauer SA, Kim J, El Chaar M, et al. Standardized outcomes reporting in metabolic and bariatric surgery. Obes Surg. 2015;25(4):587-606. DOI:10.1007/s11695-015-1645-3</mixed-citation><mixed-citation xml:lang="en">Brethauer SA, Kim J, El Chaar M, et al. Standardized outcomes reporting in metabolic and bariatric surgery. Obes Surg. 2015;25(4):587-606. DOI:10.1007/s11695-015-1645-3</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Sheehan MT. Biochemical Testing of the Thyroid: TSH is the Best and, Oftentimes, Only Test Needed – A Review for Primary Care. Clin Med Res. 2016;14(2):83-92. DOI:10.3121/cmr.2016.1309</mixed-citation><mixed-citation xml:lang="en">Sheehan MT. Biochemical Testing of the Thyroid: TSH is the Best and, Oftentimes, Only Test Needed – A Review for Primary Care. Clin Med Res. 2016;14(2):83-92. DOI:10.3121/cmr.2016.1309</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev. 2014;94(2):355-382. DOI:10.1152/physrev.00030.2013</mixed-citation><mixed-citation xml:lang="en">Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev. 2014;94(2):355-382. DOI:10.1152/physrev.00030.2013</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Романцова Т.И., Островская Е.В. Метаболически здоровое ожирение: дефиниции, протективные факторы, клиническая значимость // Альманах клинической медицины. – 2015;1(1):75-86. [Romantsova TI, Ostrovskaya EV. Metabolically healthy obesity: definitions, protective factors, clinical relevance. Almanac of clinical medicine. 2015;1(1):75-86. (In Russ.)] DOI:10.18786/2072-0505-2015-1-75-86</mixed-citation><mixed-citation xml:lang="en">Романцова Т.И., Островская Е.В. Метаболически здоровое ожирение: дефиниции, протективные факторы, клиническая значимость // Альманах клинической медицины. – 2015;1(1):75-86. [Romantsova TI, Ostrovskaya EV. Metabolically healthy obesity: definitions, protective factors, clinical relevance. Almanac of clinical medicine. 2015;1(1):75-86. (In Russ.)] DOI:10.18786/2072-0505-2015-1-75-86</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Roberson LL, Aneni EC, Maziak W. Beyond BMI: The “Metabolically healthy obese” phenotype &amp; its association with clinical/subclinical cardiovascular disease and all-cause mortality – a systematic review. BMC Public Health. 2014;14:14. DOI:10.1186/1471-2458-14-14</mixed-citation><mixed-citation xml:lang="en">Roberson LL, Aneni EC, Maziak W. Beyond BMI: The “Metabolically healthy obese” phenotype &amp; its association with clinical/subclinical cardiovascular disease and all-cause mortality – a systematic review. BMC Public Health. 2014;14:14. DOI:10.1186/1471-2458-14-14</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
